MA40894A - HETERODIMERIC IMMUNOGLOBULINS RE-TARGET CD3 / CD38 T-LYMPHOCYTES AND THEIR PRODUCTION PROCESSES - Google Patents
HETERODIMERIC IMMUNOGLOBULINS RE-TARGET CD3 / CD38 T-LYMPHOCYTES AND THEIR PRODUCTION PROCESSESInfo
- Publication number
- MA40894A MA40894A MA040894A MA40894A MA40894A MA 40894 A MA40894 A MA 40894A MA 040894 A MA040894 A MA 040894A MA 40894 A MA40894 A MA 40894A MA 40894 A MA40894 A MA 40894A
- Authority
- MA
- Morocco
- Prior art keywords
- lymphocytes
- target
- production processes
- heterodimeric immunoglobulins
- heterodimeric
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2014/073738 WO2015063339A1 (en) | 2013-11-04 | 2014-11-04 | Production of t cell retargeting hetero-dimeric immunoglobulins |
EP15167034 | 2015-05-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA40894A true MA40894A (en) | 2017-09-12 |
Family
ID=53059011
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA040894A MA40894A (en) | 2014-11-04 | 2015-11-02 | HETERODIMERIC IMMUNOGLOBULINS RE-TARGET CD3 / CD38 T-LYMPHOCYTES AND THEIR PRODUCTION PROCESSES |
Country Status (20)
Country | Link |
---|---|
EP (1) | EP3215541A1 (en) |
JP (3) | JP2018501297A (en) |
KR (1) | KR20170078831A (en) |
CN (1) | CN107207596A (en) |
AU (1) | AU2015341884B2 (en) |
BR (1) | BR112017009263A2 (en) |
CA (1) | CA2965745C (en) |
CL (1) | CL2017001090A1 (en) |
CO (1) | CO2017005240A2 (en) |
EA (1) | EA039658B1 (en) |
HK (1) | HK1244014A1 (en) |
IL (1) | IL251848A0 (en) |
MA (1) | MA40894A (en) |
MX (1) | MX2017005814A (en) |
MY (1) | MY186929A (en) |
NZ (1) | NZ732019A (en) |
PE (1) | PE20171041A1 (en) |
PH (1) | PH12017500819A1 (en) |
SG (1) | SG11201703313SA (en) |
WO (1) | WO2016071355A1 (en) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
DK2943511T3 (en) | 2013-01-14 | 2019-10-21 | Xencor Inc | NEW HETERODIMERIC PROTEINS |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
ES2683268T3 (en) | 2013-07-25 | 2018-09-25 | Cytomx Therapeutics, Inc. | Multispecific antibodies, multispecific activatable antibodies and methods for using them |
AP2016009222A0 (en) | 2013-11-04 | 2016-05-31 | Glenmark Pharmaceuticals Sa | Production of t cell retargeting hetero-dimeric immunoglobulins |
KR20230022270A (en) | 2014-03-28 | 2023-02-14 | 젠코어 인코포레이티드 | Bispecific antibodies that bind to cd38 and cd3 |
CN107108738A (en) | 2014-07-25 | 2017-08-29 | 西托姆克斯治疗公司 | Anti-cd 3 antibodies, it anti-cd 3 antibodies, polyspecific anti-cd 3 antibodies, polyspecific can be activated can activate anti-cd 3 antibodies and its application method |
US11773166B2 (en) | 2014-11-04 | 2023-10-03 | Ichnos Sciences SA | CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production |
AU2015353416C1 (en) | 2014-11-26 | 2022-01-27 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and CD38 |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
IL252480B2 (en) | 2014-11-26 | 2023-12-01 | Xencor Inc | Heterodimeric antibodies that bind cd3 and tumor antigens |
TWI829617B (en) | 2015-07-31 | 2024-01-21 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for flt3 and cd3 |
TWI796283B (en) | 2015-07-31 | 2023-03-21 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for msln and cd3 |
US11623957B2 (en) | 2015-12-07 | 2023-04-11 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and PSMA |
EA039859B1 (en) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Bispecific antibody constructs binding egfrviii and cd3 |
RU2022104399A (en) | 2016-06-14 | 2022-05-05 | Ксенкор, Инк. | BISPECIFIC ANTIBODIES-CHECKPOINT INHIBITORS |
KR20200002886A (en) * | 2017-04-24 | 2020-01-08 | 아이크노스 사이언스 에스. 아. | T cell redirecting bispecific antibodies for the treatment of EGFR positive cancer |
WO2018224441A1 (en) * | 2017-06-05 | 2018-12-13 | Numab Innovation Ag | Novel anti-cd3 antibodies |
AU2018280681A1 (en) | 2017-06-05 | 2019-12-05 | Numab Therapeutics AG | Novel anti-CD3 antibodies |
CN110997722B (en) * | 2017-06-08 | 2023-09-26 | 黑带医疗有限公司 | CD38 modulating antibodies |
CN117534754A (en) | 2017-06-08 | 2024-02-09 | 黑带医疗有限公司 | CD38 modulating antibodies |
ES2911243T3 (en) * | 2017-08-10 | 2022-05-18 | Grifols Diagnostic Solutions Inc | Compositions, methods and/or kits comprising a recombinant extracellular domain of human cd38 |
KR20200036861A (en) | 2017-08-16 | 2020-04-07 | 블랙 벨트 테라퓨틱스 리미티드 | CD38 antibody |
WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to bcma and uses thereof |
US11542338B2 (en) | 2017-08-16 | 2023-01-03 | Black Belt Therapeutics Limited | CD38 modulating antibody |
CA3078911A1 (en) | 2017-10-14 | 2019-04-18 | Cytomx Therapeutics, Inc. | Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof |
KR20210075101A (en) * | 2018-09-25 | 2021-06-22 | 아이크노스 사이언스 에스. 아. | Antibody quantification in biological samples |
KR102353568B1 (en) * | 2018-11-14 | 2022-01-20 | 주식회사 헬릭스미스 | Anti c-Met Antibody or Antigen binding fragment thereof with Improved Stability |
KR20210119448A (en) | 2019-01-23 | 2021-10-05 | 앙세파 | CD31 competitor (COMPETITOR) and uses thereof |
US20220177582A1 (en) * | 2019-03-13 | 2022-06-09 | Ichnos Sciences SA | Non-consensus glycosylation of bispecific antibodies |
TW202110887A (en) * | 2019-05-23 | 2021-03-16 | 美商維洛斯生物公司 | Anti-ror1/anti-cd3 bispecific binding molecules |
US20220227887A1 (en) * | 2019-06-11 | 2022-07-21 | Ono Pharmaceutical Co., Ltd. | Immunosuppressant |
CN110551222B (en) * | 2019-08-27 | 2023-06-06 | 重庆市畜牧科学院 | Novel bifunctional antibody and application thereof |
US20220348661A1 (en) * | 2019-09-30 | 2022-11-03 | Harbour Biomed (suzhou) Co., Ltd. | Cd3-targeting antibody, bispecific antibody and use thereof |
CN113493519B (en) * | 2020-03-19 | 2022-12-27 | 浙江道尔生物科技有限公司 | Fusion protein with remarkably prolonged half-life for treating ocular angiogenesis diseases |
US11919956B2 (en) | 2020-05-14 | 2024-03-05 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 |
KR20230028386A (en) * | 2020-06-17 | 2023-02-28 | 와이-맙스 테라퓨틱스 인코포레이티드 | CD38 antibody for treatment of human disease |
MX2023001962A (en) | 2020-08-19 | 2023-04-26 | Xencor Inc | Anti-cd28 and/or anti-b7h3 compositions. |
EP4305065A1 (en) | 2021-03-10 | 2024-01-17 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and gpc3 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE025369T2 (en) * | 2004-02-06 | 2016-02-29 | Morphosys Ag | Anti-CD38 human antibodies and uses therefor |
IL296666A (en) * | 2005-03-23 | 2022-11-01 | Genmab As | Antibodies against cd38 for treatment of multiple myeloma |
BRPI0618399B1 (en) * | 2005-10-12 | 2023-10-03 | Morphosys Ag | HUMAN ANTI-CD38 SPECIFIC ANTIBODY, NUCLEIC ACID COMPOSITION, EXPRESSION VECTOR, PHARMACEUTICAL COMPOSITION, USE OF THE ANTIBODY AND USE OF A PHARMACEUTICAL COMPOSITION |
EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
CA2766220C (en) * | 2009-06-26 | 2021-02-09 | Regeneron Pharmaceuticals, Inc. | Readily isolated bispecific antibodies with native immunoglobulin format |
ES2777901T3 (en) * | 2009-12-25 | 2020-08-06 | Chugai Pharmaceutical Co Ltd | Polypeptide Modification Method to Purify Polypeptide Multimers |
WO2011154453A1 (en) * | 2010-06-09 | 2011-12-15 | Genmab A/S | Antibodies against human cd38 |
JOP20210044A1 (en) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | Anti-cd38 antibodies |
SG10201602371VA (en) * | 2011-03-25 | 2016-04-28 | Glenmark Pharmaceuticals Sa | Hetero-dimeric immunoglobulins |
AU2013322710A1 (en) * | 2012-09-25 | 2015-04-16 | Glenmark Pharmaceuticals S.A. | Purification of hetero-dimeric immunoglobulins |
ES2621377T3 (en) * | 2012-11-05 | 2017-07-03 | Morphosys Ag | Radiolabelled antibody and uses thereof |
AP2016009222A0 (en) * | 2013-11-04 | 2016-05-31 | Glenmark Pharmaceuticals Sa | Production of t cell retargeting hetero-dimeric immunoglobulins |
-
2015
- 2015-11-02 MA MA040894A patent/MA40894A/en unknown
- 2015-11-03 SG SG11201703313SA patent/SG11201703313SA/en unknown
- 2015-11-03 CA CA2965745A patent/CA2965745C/en active Active
- 2015-11-03 JP JP2017542319A patent/JP2018501297A/en active Pending
- 2015-11-03 AU AU2015341884A patent/AU2015341884B2/en active Active
- 2015-11-03 WO PCT/EP2015/075628 patent/WO2016071355A1/en active Application Filing
- 2015-11-03 EA EA201790961A patent/EA039658B1/en unknown
- 2015-11-03 EP EP15790129.9A patent/EP3215541A1/en not_active Withdrawn
- 2015-11-03 CN CN201580072196.8A patent/CN107207596A/en active Pending
- 2015-11-03 PE PE2017000802A patent/PE20171041A1/en unknown
- 2015-11-03 NZ NZ732019A patent/NZ732019A/en unknown
- 2015-11-03 BR BR112017009263-8A patent/BR112017009263A2/en active Search and Examination
- 2015-11-03 MX MX2017005814A patent/MX2017005814A/en unknown
- 2015-11-03 MY MYPI2017701499A patent/MY186929A/en unknown
- 2015-11-03 KR KR1020177015252A patent/KR20170078831A/en not_active Application Discontinuation
-
2017
- 2017-04-23 IL IL251848A patent/IL251848A0/en unknown
- 2017-05-02 CL CL2017001090A patent/CL2017001090A1/en unknown
- 2017-05-03 PH PH12017500819A patent/PH12017500819A1/en unknown
- 2017-05-26 CO CONC2017/0005240A patent/CO2017005240A2/en unknown
-
2018
- 2018-03-12 HK HK18103440.0A patent/HK1244014A1/en unknown
-
2019
- 2019-07-23 JP JP2019135318A patent/JP2019214582A/en active Pending
-
2021
- 2021-08-02 JP JP2021126392A patent/JP7403505B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
MY186929A (en) | 2021-08-26 |
CL2017001090A1 (en) | 2018-01-05 |
BR112017009263A2 (en) | 2018-01-30 |
HK1244014A1 (en) | 2018-07-27 |
EP3215541A1 (en) | 2017-09-13 |
NZ732019A (en) | 2022-07-29 |
IL251848A0 (en) | 2017-06-29 |
AU2015341884B2 (en) | 2020-09-17 |
SG11201703313SA (en) | 2017-05-30 |
AU2015341884A1 (en) | 2017-06-08 |
CA2965745C (en) | 2023-12-05 |
JP2019214582A (en) | 2019-12-19 |
WO2016071355A1 (en) | 2016-05-12 |
PH12017500819A1 (en) | 2017-10-02 |
CA2965745A1 (en) | 2016-05-12 |
JP2018501297A (en) | 2018-01-18 |
JP7403505B2 (en) | 2023-12-22 |
PE20171041A1 (en) | 2017-07-19 |
EA201790961A1 (en) | 2017-10-31 |
CN107207596A (en) | 2017-09-26 |
EA039658B1 (en) | 2022-02-22 |
MX2017005814A (en) | 2017-08-02 |
KR20170078831A (en) | 2017-07-07 |
JP2021184722A (en) | 2021-12-09 |
CO2017005240A2 (en) | 2017-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA40894A (en) | HETERODIMERIC IMMUNOGLOBULINS RE-TARGET CD3 / CD38 T-LYMPHOCYTES AND THEIR PRODUCTION PROCESSES | |
HK1245171A1 (en) | Heterodimeric antibodies that bind cd3 and cd38 | |
HK1257164A1 (en) | Novel anti-pd-l1 antibodies | |
IL255727A (en) | Novel anti-pd-l1 antibodies | |
HK1246324A1 (en) | Anti-pd-l1 antibodies | |
IL257062A (en) | Novel anti-pd-1 antibodies | |
IL248007A0 (en) | Bispecific antibodies that bind to cd38 and cd3 | |
MA43389A (en) | ANTI-OX40 ANTIBODIES AND PROCESSES FOR USE | |
MA40889A (en) | HEREODIMERIC IMMUNOGLOBULINS RE-TARGET LYMPHOCYTES | |
SG10201603721TA (en) | Anti-CTLA-4 Antibodies | |
LT3223845T (en) | Heterodimeric antibodies that bind cd3 and cd20 | |
HK1251055A1 (en) | Automated interpretation for the layout of structured multi-field files | |
MA42829A (en) | COMPOSITIONS DERIVED FROM PLACENTA AND PROCESSES FOR PRODUCING THEM | |
MA41375A (en) | BISPECIFIC IGG ANTIBODIES AND THEIR PREPARATION PROCESSES | |
MA39915A (en) | PLADIENOLIDE PYRIDINE COMPOUNDS AND PROCESSES FOR USE | |
MA44517A (en) | RECOMBINANT INTRAVENOUS IMMUNOGLOBULIN (RIVIG) COMPOSITIONS AND PROCESSES FOR PRODUCTION AND USE | |
DK3250491T3 (en) | Product turner and placer | |
BR112017016027A2 (en) | bakery product | |
ZA201604024B (en) | Improved feeding strategies and purification processes for monoclonal antibody production | |
GB201621446D0 (en) | IL-11 antibodies | |
TH176441B (en) | Production systems and production methods for nitrogen-containing products And products that were selected from fermented / cultured products | |
TH1501005423A (en) | Adhesion molecule for BCMA and CD3 | |
ES1153808Y (en) | PACK WITH APPETIZER PRODUCTS | |
LU92551B1 (en) | IMPROVED COMPOSITIONS AND PROCESSES FOR BOROCARBOHYDRATE COMPLEXES | |
UA31746S (en) | DAIRY PRODUCT PACKAGING |